SLC5A2 and heart failure: More importantly, large cardiovascular outcome trials (CVOTs), such as EMPA-REG OUTCOME, CANVAS, and DECLARE-TIMI 58, have revealed that SGLT-2 inhibitors reduce major adverse cardiovascular events (MACE), hospitalization for heart failure, and cardiovascular mortality [6,7].